{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T12:02:12Z","timestamp":1772712132517,"version":"3.50.1"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T00:00:00Z","timestamp":1478736000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Osteosarcoma, the most common primary malignant bone tumor, usually arises in the metaphysis of long bones. Amplification and mutation of the epidermal growth factor receptor (EGFR) gene represent signature genetic abnormalities encountered in osteosarcoma. Noscapine is a benzylisoquinoline alkaloid derived from the opium poppy <jats:italic>Papaver somniferum<\/jats:italic>. Recently several studies have suggested its anti-cancer effect in melanoma, ovarian cancer, gliomas, breast cancer, lung cancer, and colon cancer. However, the underlying molecular mechanism for its anti-cancer effect still remains unclear. In this paper, we found the mechanism of noscapine effectively suppressed proliferation and invasion of MG63 cell line by inhibiting the phosphorylation of EGFR and its downstream pathway.<\/jats:p>","DOI":"10.1038\/srep37062","type":"journal-article","created":{"date-parts":[[2016,11,10]],"date-time":"2016-11-10T10:35:42Z","timestamp":1478774142000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Noscapine targets EGFRp-Tyr1068 to suppress the proliferation and invasion of MG63 cells"],"prefix":"10.1038","volume":"6","author":[{"given":"Ming","family":"He","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlin","family":"Jiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhaozhou","family":"Ren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangbin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiashi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,11,10]]},"reference":[{"key":"BFsrep37062_CR1","first-page":"93","volume":"49","author":"BM Nikitin","year":"1960","unstructured":"Nikitin, B. M. [The pathogenesis of bone sarcomas in rats following administration of strontium 89 and the effect of strontium 89 on the progeny of these animals]. Biulleten\u2019 eksperimental\u2019noi biologii i meditsiny 49, 93\u201395 (1960).","journal-title":"Biulleten\u2019 eksperimental\u2019noi biologii i meditsiny"},{"key":"BFsrep37062_CR2","doi-asserted-by":"publisher","first-page":"e90795","DOI":"10.1371\/journal.pone.0090795","volume":"9","author":"B Gobin","year":"2014","unstructured":"Gobin, B. et al. Imatinib mesylate exerts anti-proliferative effects on osteosarcoma cells and inhibits the tumour growth in immunocompetent murine models. PloS One 9, e90795, doi: 10.1371\/journal.pone.0090795 (2014).","journal-title":"PloS One"},{"key":"BFsrep37062_CR3","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1634\/theoncologist.9-4-422","volume":"9","author":"N Marina","year":"2004","unstructured":"Marina, N., Gebhardt, M., Teot, L. & Gorlick, R. Biology and therapeutic advances for pediatric osteosarcoma. The oncologist 9, 422\u2013441 (2004).","journal-title":"The oncologist"},{"key":"BFsrep37062_CR4","doi-asserted-by":"crossref","unstructured":"Poos, K. et al. Structuring osteosarcoma knowledge: an osteosarcoma-gene association database based on literature mining and manual annotation. Database: the journal of biological databases and curation 2014, doi: 10.1093\/database\/bau042 (2014).","DOI":"10.1093\/database\/bau042"},{"key":"BFsrep37062_CR5","first-page":"14","volume":"101","author":"AG Huvos","year":"1977","unstructured":"Huvos, A. G., Rosen, G. & Marcove, R. C. Primary osteogenic sarcoma: pathologic aspects in 20 patients after treatment with chemotherapy en bloc resection, and prosthetic bone replacement. Archives of pathology & laboratory medicine 101, 14\u201318 (1977).","journal-title":"Archives of pathology & laboratory medicine"},{"key":"BFsrep37062_CR6","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1002\/1097-0142(197601)37:1<1::AID-CNCR2820370102>3.0.CO;2-3","volume":"37","author":"G Rosen","year":"1976","unstructured":"Rosen, G., Murphy, M. L., Huvos, A. G., Gutierrez, M. & Marcove, R. C. Chemotherapy, en bloc resection, and prosthetic bone replacement in the treatment of osteogenic sarcoma. Cancer 37, 1\u201311 (1976).","journal-title":"Cancer"},{"key":"BFsrep37062_CR7","doi-asserted-by":"publisher","first-page":"704872","DOI":"10.1155\/2012\/704872","volume":"2012","author":"DC Allison","year":"2012","unstructured":"Allison, D. C. et al. A meta-analysis of osteosarcoma outcomes in the modern medical era. Sarcoma 2012, 704872, doi: 10.1155\/2012\/704872 (2012).","journal-title":"Sarcoma"},{"key":"BFsrep37062_CR8","doi-asserted-by":"publisher","first-page":"591","DOI":"10.3390\/cancers5020591","volume":"5","author":"K Ando","year":"2013","unstructured":"Ando, K. et al. Current therapeutic strategies and novel approaches in osteosarcoma. Cancers 5, 591\u2013616, doi: 10.3390\/cancers5020591 (2013).","journal-title":"Cancers"},{"key":"BFsrep37062_CR9","doi-asserted-by":"publisher","first-page":"1381","DOI":"10.2174\/092986707780831159","volume":"14","author":"B Ory","year":"2007","unstructured":"Ory, B., Moriceau, G., Redini, F. & Heymann, D. mTOR inhibitors (rapamycin and its derivatives) and nitrogen containing bisphosphonates: bi-functional compounds for the treatment of bone tumours. Current medicinal chemistry 14, 1381\u20131387 (2007).","journal-title":"Current medicinal chemistry"},{"key":"BFsrep37062_CR10","doi-asserted-by":"publisher","first-page":"2800","DOI":"10.1158\/0008-5472.CAN-06-3469","volume":"67","author":"AC Shor","year":"2007","unstructured":"Shor, A. C. et al. Dasatinib inhibits migration and invasion in diverse human sarcoma cell lines and induces apoptosis in bone sarcoma cells dependent on SRC kinase for survival. Cancer research 67, 2800\u20132808, doi: 10.1158\/0008-5472.CAN-06-3469 (2007).","journal-title":"Cancer research"},{"key":"BFsrep37062_CR11","doi-asserted-by":"publisher","first-page":"5579","DOI":"10.1021\/jm061449r","volume":"50","author":"F Manetti","year":"2007","unstructured":"Manetti, F. et al. Identification of a novel pyrazolo[3,4-d]pyrimidine able to inhibit cell proliferation of a human osteogenic sarcoma in vitro and in a xenograft model in mice. Journal of medicinal chemistry 50, 5579\u20135588, doi: 10.1021\/jm061449r (2007).","journal-title":"Journal of medicinal chemistry"},{"key":"BFsrep37062_CR12","doi-asserted-by":"publisher","first-page":"1198","DOI":"10.1002\/pbc.21368","volume":"50","author":"EA Kolb","year":"2008","unstructured":"Kolb, E. A. et al. Initial testing of dasatinib by the pediatric preclinical testing program. Pediatric blood & cancer 50, 1198\u20131206, doi: 10.1002\/pbc.21368 (2008).","journal-title":"Pediatric blood & cancer"},{"key":"BFsrep37062_CR13","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1002\/cncr.26339","volume":"118","author":"SE Hassan","year":"2012","unstructured":"Hassan, S. E. et al. Cell surface receptor expression patterns in osteosarcoma. Cancer 118, 740\u2013749, doi: 10.1002\/cncr.26339 (2012).","journal-title":"Cancer"},{"key":"BFsrep37062_CR14","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s002620000109","volume":"49","author":"Y Ke","year":"2000","unstructured":"Ke, Y. et al. Noscapine inhibits tumor growth with little toxicity to normal tissues or inhibition of immune responses. Cancer immunology, immunotherapy: CII 49, 217\u2013225 (2000).","journal-title":"Cancer immunology, immunotherapy: CII"},{"key":"BFsrep37062_CR15","doi-asserted-by":"publisher","first-page":"3259","DOI":"10.1158\/0008-5472.CAN-09-4230","volume":"70","author":"B Sung","year":"2010","unstructured":"Sung, B., Ahn, K. S. & Aggarwal, B. B. Noscapine, a benzylisoquinoline alkaloid, sensitizes leukemic cells to chemotherapeutic agents and cytokines by modulating the NF-kappaB signaling pathway. Cancer research 70, 3259\u20133268, doi: 10.1158\/0008-5472.CAN-09-4230 (2010).","journal-title":"Cancer research"},{"key":"BFsrep37062_CR16","doi-asserted-by":"publisher","first-page":"6459","DOI":"10.1073\/pnas.0911188107","volume":"107","author":"I Vivanco","year":"2010","unstructured":"Vivanco, I. et al. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proceedings of the National Academy of Sciences of the United States of America 107, 6459\u20136464, doi: 10.1073\/pnas.0911188107 (2010).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"BFsrep37062_CR17","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1271\/bbb.90490","volume":"74","author":"CD Wang","year":"2010","unstructured":"Wang, C. D. et al. Fangchinoline induced G1\/S arrest by modulating expression of p27, PCNA, and cyclin D in human prostate carcinoma cancer PC3 cells and tumor xenograft. Bioscience, biotechnology, and biochemistry 74, 488\u2013493, doi: 10.1271\/bbb.90490 (2010).","journal-title":"Bioscience, biotechnology, and biochemistry"},{"key":"BFsrep37062_CR18","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","volume":"5","author":"NE Hynes","year":"2005","unstructured":"Hynes, N. E. & Lane, H. A. ERBB receptors and cancer: the complexity of targeted inhibitors. Nature reviews. Cancer 5, 341\u2013354, doi: 10.1038\/nrc1609 (2005).","journal-title":"Nature reviews. Cancer"},{"key":"BFsrep37062_CR19","doi-asserted-by":"publisher","first-page":"6172","DOI":"10.1200\/JCO.2005.11.429","volume":"23","author":"NC Daw","year":"2005","unstructured":"Daw, N. C. et al. Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: a Children\u2019s Oncology Group Study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology 23, 6172\u20136180, doi: 10.1200\/JCO.2005.11.429 (2005).","journal-title":"Journal of clinical oncology: official journal of the American Society of Clinical Oncology"},{"key":"BFsrep37062_CR20","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1080\/07357900600632058","volume":"24","author":"BB Freeman 3rd","year":"2006","unstructured":"Freeman, B. B. 3rd, Daw, N. C., Geyer, J. R., Furman, W. L. & Stewart, C. F. Evaluation of gefitinib for treatment of refractory solid tumors and central nervous system malignancies in pediatric patients. Cancer investigation 24, 310\u2013317, doi: 10.1080\/07357900600632058 (2006).","journal-title":"Cancer investigation"},{"key":"BFsrep37062_CR21","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1002\/cncr.23782","volume":"113","author":"SS Freeman","year":"2008","unstructured":"Freeman, S. S. et al. Copy number gains in EGFR and copy number losses in PTEN are common events in osteosarcoma tumors. Cancer 113, 1453\u20131461, doi: 10.1002\/cncr.23782 (2008).","journal-title":"Cancer"},{"key":"BFsrep37062_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1593\/tlo.12163","volume":"5","author":"KL Mueller","year":"2012","unstructured":"Mueller, K. L., Powell, K., Madden, J. M., Eblen, S. T. & Boerner, J. L. EGFR Tyrosine 845 Phosphorylation-Dependent Proliferation and Transformation of Breast Cancer Cells Require Activation of p38 MAPK. Translational oncology 5, 327\u2013334 (2012).","journal-title":"Translational oncology"},{"key":"BFsrep37062_CR23","doi-asserted-by":"publisher","first-page":"e77270","DOI":"10.1371\/journal.pone.0077270","volume":"8","author":"HC Pal","year":"2013","unstructured":"Pal, H. C. et al. Delphinidin reduces cell proliferation and induces apoptosis of non-small-cell lung cancer cells by targeting EGFR\/VEGFR2 signaling pathways. PloS One 8, e77270, doi: 10.1371\/journal.pone.0077270 (2013).","journal-title":"PloS One"},{"key":"BFsrep37062_CR24","doi-asserted-by":"publisher","first-page":"368","DOI":"10.18632\/aging.100457","volume":"4","author":"GE Morozevich","year":"2012","unstructured":"Morozevich, G. E., Kozlova, N. I., Ushakova, N. A., Preobrazhenskaya, M. E. & Berman, A. E. Integrin alpha5beta1 simultaneously controls EGFR-dependent proliferation and Akt-dependent pro-survival signaling in epidermoid carcinoma cells. Aging 4, 368\u2013374 (2012).","journal-title":"Aging"},{"key":"BFsrep37062_CR25","doi-asserted-by":"publisher","first-page":"1714","DOI":"10.3892\/ijo.2011.1320","volume":"40","author":"LJ Xiao","year":"2012","unstructured":"Xiao, L. J. et al. ADAM17 targets MMP-2 and MMP-9 via EGFR-MEK-ERK pathway activation to promote prostate cancer cell invasion. International journal of oncology 40, 1714\u20131724, doi: 10.3892\/ijo.2011.1320 (2012).","journal-title":"International journal of oncology"},{"key":"BFsrep37062_CR26","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1089\/adt.2006.029","volume":"5","author":"A Baki","year":"2007","unstructured":"Baki, A., Bielik, A., Molnar, L., Szendrei, G. & Keseru, G. M. A high throughput luminescent assay for glycogen synthase kinase-3beta inhibitors. Assay and drug development technologies 5, 75\u201383, doi: 10.1089\/adt.2006.029 (2007).","journal-title":"Assay and drug development technologies"},{"key":"BFsrep37062_CR27","doi-asserted-by":"publisher","first-page":"2047","DOI":"10.1158\/0008-5472.CAN-03-3096","volume":"64","author":"DP Hughes","year":"2004","unstructured":"Hughes, D. P., Thomas, D. G., Giordano, T. J., Baker, L. H. & McDonagh, K. T. Cell surface expression of epidermal growth factor receptor and Her-2 with nuclear expression of Her-4 in primary osteosarcoma. Cancer research 64, 2047\u20132053 (2004).","journal-title":"Cancer research"},{"key":"BFsrep37062_CR28","doi-asserted-by":"publisher","first-page":"643","DOI":"10.1002\/ijc.11566","volume":"108","author":"MW Pedersen","year":"2004","unstructured":"Pedersen, M. W., Tkach, V., Pedersen, N., Berezin, V. & Poulsen, H. S. Expression of a naturally occurring constitutively active variant of the epidermal growth factor receptor in mouse fibroblasts increases motility. International journal of cancer. Journal international du cancer 108, 643\u2013653, doi: 10.1002\/ijc.11566 (2004).","journal-title":"International journal of cancer. Journal international du cancer"},{"key":"BFsrep37062_CR29","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1002\/ijc.21251","volume":"117","author":"XM Cai","year":"2005","unstructured":"Cai, X. M. et al. Protein phosphatase activity of PTEN inhibited the invasion of glioma cells with epidermal growth factor receptor mutation type III expression. International journal of cancer. Journal international du cancer 117, 905\u2013912, doi: 10.1002\/ijc.21251 (2005).","journal-title":"International journal of cancer. Journal international du cancer"},{"key":"BFsrep37062_CR30","first-page":"847","volume":"14","author":"Y Fukaya","year":"2005","unstructured":"Fukaya, Y. et al. A role for PI3K-Akt signaling in pulmonary metastatic nodule formation of the osteosarcoma cell line, LM8. Oncology reports 14, 847\u2013852 (2005).","journal-title":"Oncology reports"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/srep37062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37062","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/srep37062.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,5]],"date-time":"2023-01-05T00:28:25Z","timestamp":1672878505000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/srep37062"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,10]]},"references-count":30,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2016,12,23]]}},"alternative-id":["BFsrep37062"],"URL":"https:\/\/doi.org\/10.1038\/srep37062","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,10]]},"assertion":[{"value":"20 July 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 October 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"37062"}}